Business / Finance

RSS

GE Capital supports eBioscience with $55 million in senior secured credit facilities

GE Capital, Healthcare Financial Services announced today that it is agent and a lender for $55 million in senior secured credit facilities for eBioscience, Inc. The credit facilities will be used to finance the company's repurchase of certain shares from early investors, refinance existing debt, and provide growth capital.

11 Feb 2011

UFRF files lawsuit against Diamyd Medical

The University of Florida Research Foundation Inc. (UFRF) has filed a lawsuit in United States federal district court in Florida against Diamyd Medical claiming that UFRF is entitled to a percentage of the license fee paid to Diamyd Medical by Ortho-McNeil-Jansen Pharmaceuticals, Inc. (OMJPI).

11 Feb 2011

SeraCare first quarter revenue decreases 7% to $10.5 million

SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its first quarter of fiscal year 2011, ended December 31, 2010.

11 Feb 2011

AcelRx prices initial public offering at $5.00 per share

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.

11 Feb 2011

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

The Board of Directors of Sorin S.p.A. meeting today under the chairmanship of Rosario Bifulco reviewed the fourth quarter 2010 and the preliminary 2010 consolidated results.

11 Feb 2011

Bradmer Pharmaceuticals records net loss of $117,000 for fourth quarter of 2010

Bradmer Pharmaceuticals Inc. today announced its 2010 fourth quarter and fiscal year operational and financial results.

10 Feb 2011

Agilent Technologies acquires specific assets of A2 Technologies

Agilent Technologies Inc. has completed the acquisition of specific assets of A2 Technologies. Financial details were not disclosed for the acquisition, which was first announced Jan. 19.

10 Feb 2011

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.

10 Feb 2011

NeoGenomics fourth quarter revenue increases 12% to $8.8 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter 2010 and fiscal year ended December 31, 2010.

10 Feb 2011

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2010.

10 Feb 2011

Edward Hospital joins Premier healthcare alliance and saves $1,053,000

Edward Hospital & Health Services has saved more than $1 million by joining the Premier healthcare alliance. The full-service, regional healthcare provider based in Naperville, Ill., is also participating in programs to provide high-quality, cost-effective care.

10 Feb 2011

LabCorp fourth quarter net earnings decrease to $131.8 million

Laboratory Corporation of America® Holdings today announced results for the quarter and year ended December 31, 2010. These results include the operations of Genzyme Genetics for the month of December.

10 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

MEDTOX Scientific fourth quarter total revenues increase 25.7% to $25.0 million

MEDTOX Scientific, Inc. today announced fourth quarter and year-end results for the periods ended December 31, 2010.

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

10 Feb 2011

Biotage fourth quarter net sales increase 17% to 116.1 MSEK

Net sales increased by 17 percent to 116.1 MSEK (99.5). At comparable exchange rates sales increased by 23 percent and at comparable exchange rates excluding business acquired during the year net sales remained at the same level as last year.

10 Feb 2011

Benson Group listed on 'Europe's 500' top growth companies

Europe's 500, the association of top European growth entrepreneurs met at the European Parliament in Brussels on February 3rd for the European Growth Summit 2011. An integral part of the event, the "Europe's 500" awards ceremony honoured the top-growth-companies in Europe, and released a list of the 200 fastest-growing, job-creating businesses.

10 Feb 2011

Artimplant fourth quarter net revenue decreases to SEK 3.5 million

Net revenue for the fourth quarter amounted to SEK 3.5 million (5.8) and for January-December SEK 18.5 million (24.0).

10 Feb 2011

Growing number of organizations decide not to drop health-care coverage for employees

While most organizations are not waiting for a repeal of health-care reform, many are looking for further guidance on specific provisions of the law before making decisions on their benefits plans, a new poll by the Society for Human Resource Management (SHRM) found.

10 Feb 2011